New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Check below for free stories on GOOG;EMC;VMW;INTC;GILD;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 10, 2014
06:49 EDTGOOGMotorola Mobility names Osterloh COO
Subscribe for More Information
06:29 EDTGOOGAT&T in talks to bring ultrafast internet to North Carolina, WSJ reports
Subscribe for More Information
06:13 EDTINTCIntel to launch Haswell Refresh CPUs, 9-series chipsets in May, DigiTimes says
Subscribe for More Information
05:37 EDTGILDGilead announces Phase 2 results for investigational sofosbuvir-based regimens
Gilead Sciences announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, for the treatment of chronic hepatitis C virus, or HCV, infection. The first study, ELECTRON2, is an ongoing, open-label Phase 2 clinical trial evaluating a once-daily fixed-dose combination of SOF 400 mg and the NS5A inhibitor ledipasvir, or LDV, 90 mg, with and without ribavirin, or RBV, twice-daily, among HCV-infected patient populations. In this study, 100% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF plus RBV and 64% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF without RBV achieved a sustained virologic response 12 weeks after completing therapy. Among genotype 1-infected patients who had failed prior treatment with SOF plus RBV, 100% achieved SVR12 following 12 weeks of LDV/SOF plus RBV. Additionally, 65% of genotype 1-infected patients with decompensated or Child-Turcotte-Pugh Class B cirrhosis receiving 12 weeks of LDV/SOF without RBV achieved SVR12. LDV/SOF with and without RBV was well-tolerated, including among patients with more advanced liver disease. A second study, Study GS-US-342-0102, is an ongoing randomized Phase 2 clinical trial in which treatment-na´ve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg or GS-5816 100 mg. In this study, 94.8% of patients receiving the 25 mg dose of GS-5816 and 96.1% of patients receiving the 100 mg dose achieved SVR12.
05:32 EDTGILDGilead announces results from study of Sovaldi
Subscribe for More Information
April 9, 2014
16:00 EDTGILDOptions Update; April 9, 2014
Subscribe for More Information
11:51 EDTGILDStocks with call strike movement; AAL GILD
American Airlines (ALL) August 44 call option implied volatility increased 4% to 39, Gilead (GILD) August 80 call option implied volatility decreased 2% to 34 according to IVolatility.
11:43 EDTGILDGilead defended by analysts after recent pullback
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:58 EDTGOOGGoogle Q1 results should beat expectations, says Susquehanna
Susquehanna is bullish on Google heading into Q1 results on expectations of continued website growth from mobile share gains, PLAs, early benefits from Enhanced Campaigns, and YouTube. The firm sees the company beating Street revenue estimates by 1% and earnings by 5%. Shares are Positive rated with a $700 price target
08:41 EDTGILDAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
08:24 EDTGOOGGoogle, Apple have considered acquiring Square, Re/code reports
Subscribe for More Information
08:04 EDTVMWCitrix survey indicates weak demand fundamentals, says Jefferies
Subscribe for More Information
07:56 EDTGILDGilead poised for strong earnings, says RW Baird
Subscribe for More Information
07:28 EDTGOOGAmazon looking to court game developers for Fire TV, NY Post reports
Subscribe for More Information
07:23 EDTGILDEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:00 EDTINTCBofA, Intel fire 3K workers, leaving Costa Rica shocked, Bloomberg says
Subscribe for More Information
06:20 EDTGOOGGoogle adds more photos, reviews to hotel business, WSJ says
Subscribe for More Information
06:20 EDTINTCIntel plans 1,500 job cuts in Cosa Rica, WSJ reports
Intel is planning to lay off about 1,500 employees in Costa Rica, the Wall Street Journal reports. The company will move longtime assembly and test operations in the country to three locations in Asia. The latest job cuts reduce Intel's workforce by about 1.4%. Reference Link
05:50 EDTFRXForest Labs reports FDA provided feedback on combination aclidinium, formoterol
Forest Laboratories announced that they have recently received feedback from the FDA regarding the fixed dose combination of aclidinium and formoterol. Although no new issues have arisen, further discussion is needed with the Agency in order to address questions related to CMC, or Chemistry, Manufacturing and Control, and a Type C meeting with the FDA is going to be requested, likely to be held during Q3 this year. Forest and Almirall believe that the fixed dose combination of aclidinium and formoterol can be an important therapy for U.S. COPD patients.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use